Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis

KORUK, İrfan; YILMAZ, Ömer; YILMAZ, Arif; CAYIR, Kerim; Koruk, Mehmet

Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis

Ömer YILMAZ, (Atatürk Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Erzurum, Türkiye)

İrfan KORUK, (Avukat Cengiz Gökçek Devlet Hastanesi, Gaziantep, Türkiye)

Kerim CAYIR, (Atatürk Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Erzurum, Türkiye)

Mehmet KORUK, (Gaziantep Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Gaziantep, Türkiye)

Arif YILMAZ (Rize Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Rize, Türkiye)

Uluslararası Hematoloji-Onkoloji Dergisi

1 1

Yıl: 2009 Cilt: 19 Sayı: 1 Sayfa Aralığı: 23 - 27 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis

Öz:

İnsülin benzeri büyüme faktörü-1 (IGF-1), etkisi insülin benzeri büyüme faktör bağlayıcı protein-3 (IGFBP-3) tarafından düzenlenen, potent bir mitojen ve antiapoptotik ajandır. IGFBP-3, IGF-1’i dolaşımda taşır, hedef dokulara yönlendirir, onu proteolitik degradasyondan korur. IGFBP-3 in vitro şartlarda kolon kanser hücrelerinin tümörojenik potansiyellerini azaltır. IGFBP-3 hedef hücreleri doğrudan inhibe edebilir.Çalışmamızda kolorektal kanserli hastalarda IGF-I, IGFBP-3’ün tümör markırı olarak kullanılıp, kullanılamayacağı ve bilinen tümör markırlarından karsinoembriyonik antijen (CEA), karbonhidrat antijeni 19-9 (CA19-9) ile olan ilişkisi incelendi. Çalışmamıza histopatolojik olarak kolorektal kanser teşhisi konulmuş 40 hasta ile, kontrol grubu olarak benzer yaş grubundan ve tamamen sağlıklı 40 kişi dahil edildi.Kontrol grubu ile kıyaslandığında kolorektal kanserli hastalarda IGF-I düzeyi anlamlı derecede yüksek bulundu (p< 0.01). IGFBP-3 düzeyleri kolorektal kanserde kontrol grubu ile kıyaslandığında anlamlı derecede düşük bulundu (p< 0.05). Yine aynı vakalarda çalışılan CEA ve CA19-9 düzeylerinde gözlenen artış kontrol grubu ile kıyaslandığında istatistiki açıdan anlamlı olarak yüksek bulundu (p< 0.05). Fakat IGF-1 ve IGFBP-3 düzeylerindeki değişimi ile CEA ve CA 19-9 arasında anlamlı ilişki tespit edilemedi. Sonuç olarak, IGF-I düzeyindeki artış, kolorektal kanser şüphesi olan hastalarda tümör varlığı yönünden anlamlı bir gösterge olarak kabul edilebilir. IGFBP-3 düzeyini artışına neden olabilecek ajanlar kolorektal kanser tedavisinde yeni ufuklar açabilir.

Anahtar Kelime: Tanı Kolorektal neoplazmlar İnsülin-benzeri büyüme faktörü I İnsülin-benzeri büyüme faktörü bağlayıcı protein 3 CA-19-9 antijen

Konular: Onkoloji

Kolorektal kanser tanısında insülin benzeri büyüme faktörü-1 (IGF-1) ve insülin benzeri büyüme faktör bağlayıcı protein-3 (IGFBP-3)’ün kullanılabilirliği

Öz:

Insulin-like growth factor (IGF-1) is a potent mitogen and an anti-apoptotic agent which is regulated by insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 carries IGF-1 through the bloodstream to the target tissues and protects it from proteolytic degradation. IGFBP-3 reduces tumorigenic potential of colon cancer cells in vitro. IGFBP- 3 may inhibit target cells directly. In the present study, we assessed whether serum levels of IGF-I and IGFBP-3 could be used as tumor markers in patients with colorectal cancers and evaluated its relationship with known tumor markers, carcinoembryogenic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).Our study enrolled 40 patients diagnosed with colorectal cancer histopathologically and 40 completely healthy, agematched subjects (control group). Serum IGF-I levels were found significantly higher in patients with colorectal cancers compared to control group (p< 0.01). Serum IGFBP-3 levels were significantly lower in patients with colorectal cancers compared to control group (p< 0.05). The observed increase in CEA and CA19-9 levels in the same subjects were found statistically significantly higher compared to control group (p< 0.05). However, no significant association could be found between change in IGF-1 and IGFBP-3 levels and CEA or CA 19-9. Increased serum levels of IGFI might be considered as a significant predictor of tumor presence in patients with suspected colorectal cancer. Agents that could increase IGFBP-3 levels might be promising for the treatment of colorectal cancers.

Anahtar Kelime: Insulin-Like Growth Factor Binding Protein 3 CA-19-9 Antigen Diagnosis Colorectal Neoplasms Insulin-Like Growth Factor I

Konular: Onkoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Jacobs EL , Haskell CM. Clinical use of tumor markers in oncology. Curr Probl Cancer 6: 301-338, 1991.
2. Minton JB, Chevinsky A. Present status of serum markers. Semin Surg Oncol 14: 102-138,1987
3. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 65: 311-320, 1992.
4. Durai R, Yang W, Gupta S, et al. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 20: 203-220, 2005.
5. Morimoto LM, Newcomb PA, White E, et al. Insulin- like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 14: 1204-1211, 2005.
6. Morimoto LM, Newcomb PA, White E, et al. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 14: 1394-1401, 2005.
7. Williams AC, Collard TJ, Perks CM, et al. Increased p53-dependent apoptosis by the insulinlike growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 60: 22-27, 2000.
8. Samani AA, Yakar S, Leroith D, et al. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28: 20-47, 2007.
9. Keku TO, Lund PK, Galanko J, et al. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev14:2076-2081, 2005.
10. Hergenç G. Şahin H. Kanser tanı ve prognozunda tümör belirteçlerinin önemi. Sendrom 4:50-55, 1994.
11. Ferrigno D, Buccheri G, Biggi A. Serum tumor markers in lung cencer: History, biology and clinical applications. Eur Respir J 7: 186-197,1994.
12. Gold P, Fredman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 122: 439-462, 1965.
13. Booth SN, King JPG, Leonard JC, et al. Serum carcinoembriyonic antigen in clinical disorders. Gut 14: 794-799, 1973.
14. Lundin J, Roberts PJ , Kuusela P, et al. The prognostic value of preoperative serum levels of Ca 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 69: 515-519, 1994.
15. Angel JA, Praat CB, Rao BN, et al. CEA and carbonhydrate 19-9 antigen as markers for colorectal carcinoma in children and adolescents. Cancer 69: 1487-1491, 1992.
16. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244, 2000.
17. Renehan AG, Zwahlen M, Minder C, et al. Insulin- like growth factor (IGF)-I, IGF binding protein- 3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353, 2004.
18. Hoppener JVM, Moseman S, Roholl PJM, Lambrechts C. Expression of IGF-I and II genes in human smooth muscle tumors. EMBO J 7:1379-1395, 1988
19. Wu Y, Yakar S, Zhao L, et al. Circulating insulin- like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62:1030-1035, 2002.
20. Giovannucci E. Insulin-like growth factor-I and binding protein-III and risk of cancer. Horm Res 51: 34-41, 1999.
21. Mishra L, Bass B, Ooi BS, et al. Role of insülinlike growth factor-I receptor I and IGF binding protein-II in human colorectal cancer. Growth Horm IGF Res 8: 473-479, 1998.
22. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of IGF-I and IGFBP-III. J Natl Cancer Inst 91: 620-625, 1999.
23. Giovannucci E, Pollak M, Platz EA, et al. A prospective study of plasma insulin-like growth factor-I and binding protein-III and risk of colorectal neoplasia in women. Cancer Epidemology 9: 345-349, 2000.
24. Manousos O, Souglakos J, Cristina Bosetti, et al. IGF-I and IGF-II in relation to colorectal cancer Int J Cancer 83: 15-17, 1999.
25. Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepatogastroenterology 46: 905-908, 1999.
26. Nakayama T, Watanabe M, Teramoto T, et al. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients. Anticancer Res 17: 1379-1382, 1997.

APA	YILMAZ Ö, KORUK İ, CAYIR K, Koruk M, YILMAZ A (2009). Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. , 23 - 27.
Chicago	YILMAZ Ömer,KORUK İrfan,CAYIR Kerim,Koruk Mehmet,YILMAZ Arif Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. (2009): 23 - 27.
MLA	YILMAZ Ömer,KORUK İrfan,CAYIR Kerim,Koruk Mehmet,YILMAZ Arif Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. , 2009, ss.23 - 27.
AMA	YILMAZ Ö,KORUK İ,CAYIR K,Koruk M,YILMAZ A Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. . 2009; 23 - 27.
Vancouver	YILMAZ Ö,KORUK İ,CAYIR K,Koruk M,YILMAZ A Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. . 2009; 23 - 27.
IEEE	YILMAZ Ö,KORUK İ,CAYIR K,Koruk M,YILMAZ A "Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis." , ss.23 - 27, 2009.
ISNAD	YILMAZ, Ömer vd. "Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis". (2009), 23-27.

APA	YILMAZ Ö, KORUK İ, CAYIR K, Koruk M, YILMAZ A (2009). Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. Uluslararası Hematoloji-Onkoloji Dergisi, 19(1), 23 - 27.
Chicago	YILMAZ Ömer,KORUK İrfan,CAYIR Kerim,Koruk Mehmet,YILMAZ Arif Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. Uluslararası Hematoloji-Onkoloji Dergisi 19, no.1 (2009): 23 - 27.
MLA	YILMAZ Ömer,KORUK İrfan,CAYIR Kerim,Koruk Mehmet,YILMAZ Arif Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. Uluslararası Hematoloji-Onkoloji Dergisi, vol.19, no.1, 2009, ss.23 - 27.
AMA	YILMAZ Ö,KORUK İ,CAYIR K,Koruk M,YILMAZ A Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. Uluslararası Hematoloji-Onkoloji Dergisi. 2009; 19(1): 23 - 27.
Vancouver	YILMAZ Ö,KORUK İ,CAYIR K,Koruk M,YILMAZ A Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis. Uluslararası Hematoloji-Onkoloji Dergisi. 2009; 19(1): 23 - 27.
IEEE	YILMAZ Ö,KORUK İ,CAYIR K,Koruk M,YILMAZ A "Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis." Uluslararası Hematoloji-Onkoloji Dergisi, 19, ss.23 - 27, 2009.
ISNAD	YILMAZ, Ömer vd. "Usefullness of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) for colorectal cancer diagnosis". Uluslararası Hematoloji-Onkoloji Dergisi 19/1 (2009), 23-27.